Evidence map›Paper›PMID 41848549›Full record

ArticleHuman vaccines & immunotherapeutics2026

Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: A Canadian Immunization Research Network study.

Michael Smolinski, Jo Lin Chew, Cora Constantinescu, C Arianne Buchan, Catherine Burton, Alex Carignan, Lana A Castellucci, Sneha Suresh, Athena McConnell, Shaun K Morris and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michael SmolinskiInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Jo Lin ChewDepartment of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Cora ConstantinescuAlberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
C Arianne BuchanInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Catherine BurtonDepartment of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Alex CarignanDepartment of Microbiology and Infectious Diseases, Faculté de médecine et de Sciences de la santé, Universite de Sherbrooke, Sherbrooke, QC, Canada.
Lana A CastellucciInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Sneha SureshDepartment of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Athena McConnellDepartment of Pediatrics, Jim Pattison Children's Hospital, University of Saskatchewan, Saskatoon, SK, Canada.
Shaun K MorrisDivision of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Monika NausSchool of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Jeffrey M PernicaDepartment of Pediatrics, McMaster University, Hamilton Health Sciences, Hamilton, ON, Canada.
Anne Pham-HuyDivision of Infectious Diseases, Immunology and Allergy, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.
Pierre-Philippe Piche-RenaudDivision of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Manish SadaranganiVaccine Evaluation Center, BC Children's Hospital Research Institute, Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Karina A TopDepartment of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Juthaporn CowanInflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, ON, Canada.ORCID 0000-0001-6648-5109
Special Immunization Clinic Network investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on safety of revaccination after a hematologic adverse event following immunization (AEFI) with COVID-19 vaccines are limited. This study characterized hematologic AEFIs in patients assessed by Canadian Special Immunization Clinic (SIC) network physicians from January 2021 to February 2023 and estimated recurrence rates of hematologic events after revaccination. Following clinical assessment of 475 individuals, revaccinated participants were followed for recurrence of AEFI. Thirty-eight cases (21 [55.3%] males and 17 [44.7%] females) with hematologic AEFIs and aged ≥12 were included in the analysis; 31/38 participants (81.6%) were 18 to 64 y old. Immune thrombocytopenia, deep vein thrombosis and pulmonary embolism were the most common diagnoses, accounting for 11 (28.9%), 9 (23.7%) and 9 (23.7%), cases. Two cases of thrombosis with thrombocytopenia syndrome (TTS) were reported after ChAdOx1. The vaccines associated with hematologic AEFIs were BNT162b2 (17, 44.7%), ChAdOx1 (11, 28.9%), and mRNA-1273 (10, 26.3%). Twenty-seven (71.1%) participants were revaccinated; 14 (51.9%) received the same vaccine product as their initial vaccine while 13 (48.1%) received a different product. There were no recurrences of the same AEFI reported after revaccination with an mRNA vaccine, including the two patients with TTS, suggesting that hematologic AEFI recurrences following COVID-19 vaccines are likely uncommon.

Indexed as

COVID-19COVID-19 VaccinesHematologic DiseasesImmunization, SecondaryAdolescentAdultBNT162 VaccineCanadaChAdOx1 nCoV-19ChildFemaleHumansMaleMiddle AgedPulmonary EmbolismPurpura, Thrombocytopenic, IdiopathicBNT162 VaccineChAdOx1 nCoV-19COVID-19 Vaccinesadverse eventsCOVID-19 vaccinehematologicrevaccinationvaccine safety

Identifiers

PMID41848549
PMCPMC13003850

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.